MSLN Antibody
- Known as:
- MSLN Antibody
- Catalog number:
- csb-pa015044esr1hu
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- CusAb
- Gene target:
- MSLN Antibody
Related genes to: MSLN Antibody
- Gene:
- MSLN NIH gene
- Name:
- mesothelin
- Previous symbol:
- -
- Synonyms:
- CAK1, MPF
- Chromosome:
- 16p13.3
- Locus Type:
- gene with protein product
- Date approved:
- 1999-11-22
- Date modifiied:
- 2015-08-25
Related products to: MSLN Antibody
Related articles to: MSLN Antibody
- Chimeric antigen receptor (CAR)-T cell therapies have revolutionized the landscape of cancer treatment, particularly in hematological malignancies. However, their successful translation to solid tumors remains limited by several barriers, including immunosuppressive tumor microenvironment and on-target/off-tumor toxicity. One promising strategy to enhance efficacy of CAR-T cells is the rational selection of tumor-specific antigens coupled with engineering strategies that incorporate localized immune modulation, such as CAR-T cells secreting immune checkpoint-blocking anti-PD-L1 scFv. - Source: PubMed
Publication date: 2026/06/26
Phanthaphol NattapornKanoksing PattaraRiansuwan WoraminPrapasrivorakul SiriluckOvartchaiyapong PornraksaMongkhonsupphawan AitsariyaPhumphuang SuratJunking MutitaThuwajit PetiYenchitsomanus Pa-ThaiThuwajit ChanitraThongchot Suyanee - Intravesical therapies are the mainstay of bladder cancer (BCa) management, but their efficacy is limited by toxicities and recurrences. While CAR T cell therapy has shown promise in hematologic malignancies, its application in solid tumors is limited by poor trafficking and on-target off-tumor toxicities. Here, we identify and validate MUC16 as a clinically relevant target for BCa, noting enriched expression in tumors recalcitrant to existing therapies. We engineered a second-generation mesothelin-based CAR (MSLN-28z) and demonstrated robust activity across multiple BCa cell lines and patient-derived tumor organoids. Intravesical delivery of MSLN-28z CAR T cells in xenograft BCa models conferred superior tumor control compared with intravenous transfer, while attenuating systemic T cell engraftment. Intravesical adoptive transfer uncouples local antitumor efficacy from potential systemic toxicity-a feature conserved across several T cell immunotherapies with on-target off-tumor activity. Collectively, these findings substantiate MUC16 as a therapeutic candidate and validate intravesical delivery as a platform for T cell immunotherapies in the management of organ-confined BCa. - Source: PubMed
Publication date: 2026/06/26
Abrahimi ParwizKhan Jonathan FDuren-Lubanski AlyssaCai WinsonMarouf YacineChen NanHirschhorn DanielMammone RenataMiranda Ileana CTallman Jacob EVela-Moreno AlejandraHamieh MohamadFaltas Bishoy MCarroll Thomas MEveritt Micaela LSubramanian Hari K KAl-Ahmadie Hikmat AElemento OlivierHopkins Benjamin DScherr Douglas SBrentjens Renier JWolchok Jedd DMerghoub Taha - Cancer immunotherapy faces persistent limitations due to its reliance on single-signal therapeutic architectures, which are vulnerable to antigen loss, off-tumor toxicity, and tumor heterogeneity. A fundamental contributor to therapeutic failure is the generation of biological decision errors - false-positive activation in normal tissues and false-negative missed recognition in antigen-low tumors. - Source: PubMed
Publication date: 2026/06/03
Kalondero Emery M - Chimeric antigen receptor-engineered natural killer (CAR-NK) cells have emerged as a promising strategy for cancer immunotherapy; however, their efficacy against solid tumors remains limited by inefficient tumor trafficking and impaired cytotoxic function within the tumor microenvironment. Here, we investigated whether a non-genetic chemical priming strategy could pre-arm CAR-NK cells and enhance their migratory and cytotoxic functions. - Source: PubMed
Publication date: 2026/06/01
Ryu Ki SeoPark HailMaeng EunchongLim Jun-YeonCho DuckChoi Seung HeePark Kyung-Soon - Malignant pleural mesothelioma (MPM) is a rare and highly aggressive malignancy arising from the pleural lining, characterized by a dismal prognosis and limited therapeutic options. Mesothelin (MSLN)-directed chimeric antigen receptor (CAR)-armored T (CAR-T) cell therapies have shown encouraging preliminary outcomes; however, autologous manufacturing approaches remain constrained by logistical complexity and prolonged production timelines, which are suboptimal for patients with rapidly advancing disease. Here, we describe the development of human allogeneic interleukin-15-augmented, MSLN-specific, CAR-armored invariant natural killer T (MCAR-NKT) cells. These cells are generated through genetic modification of hematopoietic stem and progenitor cells, followed by a clinically guided CAR-NKT cell differentiation, maturation, and expansion process. This approach supports scalable production with high cellular yield, purity, and translational feasibility. Functionally, MCAR-NKT cells exhibit robust antitumor efficacy in vitro and demonstrate robust therapeutic activity across multiple in vivo MPM xenograft models, including subcutaneous and lung metastasis models. In addition, they actively modulate the tumor microenvironment by targeting CD1d tumor-associated macrophages. Phenotypic analysis reveals a rejuvenated cellular profile, marked by low expression of exhaustion-associated and inhibitory receptors, including PD-1, TIM-3, LAG-3, CTLA-4, and TIGIT, consistent with sustained functional capacity. Importantly, these cells display a favorable safety profile, with minimal evidence of graft-versus-host disease, cytokine release syndrome, brain infiltration or neurotoxicity, and no detectable off-tumor effects. Collectively, these findings support the development of a clinically translatable, off-the-shelf CAR-NKT cell therapy for the treatment of MPM. - Source: PubMed
Publication date: 2026/06/11
Li Yan-RuideZhu YichenLi ZheShen XinyuanLi ShuoChen YuningLyu ZibaiHuang JieMa Nathan YZhang CatherineZhao Annabel STian YanxinZhou Xianghong JasmineYang Lili